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Summary Monoclonal antibodies (Mabs) from the Second International Workshop on Small Cell Lung
Cancer (SCLC) Antigens that recognise the cluster 2 SCLC-associated antigen mediated potent and selective
cytotoxic effects in an indirect assay of immunotoxin cytotoxicity. In this assay, the NCI-H69 cell line was
treated with each Mab at 4°C, washed to remove unbound Mab, and then incubated at 37°C in the presence of
a fixed concentration, 1 x 10-8 M, of the screening agent, sheep anti-mouse IgG-ricin A chain. The use of a
fixed high concentration of screening agent led to a 300-fold overestimate of the potency of a cluster 2-directed
immunotoxin, MOC-31-ricin A chain. In contrast, when the concentration of the screening agent was identical
to the Mab concentration, a precise match to immunotoxin potency was obtained. MOC-31-ricin A chain
selectivity inhibited the incorporation of [3H]leucine by the NCI-H69, SW2 and GLC-8 SCLC cell lines by
50% at a concentration between 3 x 10-" M and 3 x 10`0 M, and by the NCI-H125 lung adenocarcinoma cell
line at 7 x 10-" M, but exerted no selective toxic effects upon human lung and non-lung tumour cell lines
lacking surface expression of the cluster 2 antigen.
Small cell lung cancer (SCLC) is a metastatic malignancy
characterised by high initial response rates to conventional
chemotherapy and the consequent emergence of drug resis-
tance (Minna et al., 1989). New anti-tumour agents that have
the potential to act systemically and by novel mechanisms
able to circumvent drug resistance could make a significant
contribution to the treatment of SCLC. We have recently
begun to investigate the potential of immunotoxins made by
linking ricin A chain to monoclonal antibodies (Mabs) recog-
nising SCLC-associated antigens (Wawrzynczak et al., 1990,
1991, 1992; Derbyshire et al., 1992). Ricin A chain
immunotoxins have been administered to cancer patients
systemically and selectively intoxicate target cells by inac-
tivating ribosomes (Wawrzynczak, 1992; Wawrzynczak &
Derbyshire, 1992).
Two international workshops on SCLC antigens have
defined eight clusters of Mabs which react with distinct cell
surface antigens associated with SCLC (Souhami et al., 1987,
1991). In a preliminary study using an indirect assay of
immunotoxin cytotoxicity, we identified that cluster 2 Mabs
from the Second International Workshop were generally
effective in delivering ricin A chain to the cytosol (Derbyshire
& Wawrzynczak, 1991). From these results, we predicted that
an immunotoxin made by the direct chemical linkage of ricin
A chain to a cluster 2 Mab should be selectively and potently
toxic to SCLC cell lines. In this study, we have constructed a
cluster 2 immunotoxin, MOC-31-ricin A chain, determined
its cytotoxic properties using a panel of human tumour cell
lines, and have examined the factors influencing the selec-
tivity and accuracy of the indirect assay.
Materials and methods
Monoclonal antibodiesfrom the Second International
Workshop on SCLC Antigens
Monoclonal antibody solutions distributed as part of the
Second International Workshop on SCLC Antigens were
either in the form of hybridoma supernatants or as dilutions
of ascites/purified Mab at similar concentration. The cluster
2 Mabs from the Workshop panel that bound to greater than
95% of cells of the NCI-H69 SCLC line included the mouse
Mabs MOC-31, MOC-151, PE-35, and AUAI of the IgGI
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isotype, SL2.21 of the IgG2a isotype, MOC-58 and MOC-
181 of undetermined isotypes, and the rat Mab LCA2 of the
IgG2a isotype (Beverley et al., 1991).
Preparation ofimmunotoxins
The mouse Mab MOC-31, of the IgG1 isotype (de Leij et al.,
1986), recognises the SCLC-associated cluster 2 antigen
(Beverley et al., 1988). The mouse Mab W3/25, also of the
IgGl isotype and recognising the rat homologue of the
human CD4 antigen, was used as an irrelevant control Mab.
The Mabs were linked to ricin A chain via a disulphide bond
according to the procedure described by Cumber & Wawr-
zynczak (1992). Briefly, the purified Mab was reacted with
N-succinimidyl 3-(2-pyridyldithio)propionate to introduce an
average of about two 2-pyridyldisulphide groups into the
Mab. The derivatised Mab was allowed to react overnight
with a 2.5-fold molar excess of freshly reduced ricin A chain
and the mixture was applied to a column of Sephacryl
S200(HR). Protein fractions of eluate were analysed by
sodium dodecyl sulphate polyacrylamide gel electrophoresis
and fractions corresponding to conjugate molecules consis-
ting predominantly of one ricin A chain molecule linked to
one Mab molecule were pooled to form the final preparation
of immunotoxin.
Immunotoxin screening agents for use with mouse and rat
Mabs were prepared by chemically linking ricin A chain to
the Fab' fragments of sheep anti-mouse IgG (SAMIgG) and
sheep anti-rat Ig (SARIg) respectively (Wawrzynczak et al.,
1990; Derbyshire & Wawrzynczak, 1991).
Cell lines
The panel of human SCLC cell lines comprised the classic
GLC-8 line (Postmus et al., 1988), the classic NCI-H69 line
(Carney et al., 1985) provided by Dr L. Kelland at the
Institute of Cancer Research, Sutton, UK and the variant
SW2 line provided by Dr R. Stahel at the University Hos-
pital, Zurich, Switzerland. The lung adenocarcinoma cell
lines NCI-H23 and NCI-H125 (Carney et al., 1985) were
provided by Dr V. Macauley at the Institute of Cancer
Research, Sutton, UK. The human T-lymphoblastoid cell
line CEM was obtained from the American Type Tissue
Culture Collection.
Cell lines were maintained in a humidified atmosphere of
5% CO2 in air at 37°C. The lines were cultured in RPMI-
1640 supplemented with 10% (v/v) heat inactivated foetal
calf serum, 2mM L-glutamine, 100IUml-' penicillin, and
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100 tg ml-' streptomycin. SCLC cells growing as aggregates
in suspension and adenocarcinoma cell lines growing as
monolayer cultures were disaggregated to predominantly sin-
gle cells for use in experiments as described previously
(Wawrzynczak et al., 1990). The T-lymphoblastoid cell line
grew as a suspension of single cells in tissue culture. Cell
suspensions for cytotoxicity assays were prepared in medium
containing leucine-free RPMI (assay medium).
Indirect immunofluorescence analysis ofMab binding to
NCI-H69 cells
NCI-H69 cells were adjusted to a density of 1 x 106 cells
ml-' in assay medium and mixed with an equal volume of
each of the cluster 2 Mab samples from the Second Interna-
tional Workshop. The cells were incubated on ice for 30 min
and indirect immunofluorescence and flow cytometry was
performed as described previously (Derbyshire & Wawrzync-
zak, 1991). The relative mean fluorescence intensity (MFI) of
single live NCI-H69 cells was measured.
Cytotoxicity assays
The indirect assay of immunotoxin cytotoxicity was per-
formed essentially as described previously (Derbyshire &
Wawrzynczak, 1991). Briefly, cell suspensions at a density of
1 x 105 cells ml-', which had been pretreated with Mabs and
washed, were incubated for 48 h at 37°C in the presence of
the screening agent at a fixed concentration of 1 X 10-8 M or
in its absence. The cultures were incubated for a further 4 h
in the presence of 1 1tCi of [3H]leucine, were then harvested
and counted for [3H]leucine incorporation.
The continuous cytotoxicity assays were performed essen-
tially as described previously (Wawrzynczak et al., 1990).
Briefly, cells suspensions at a density of 1 x 105 cells ml-'
were incubated for 48 h at 37°C in the presence of
immunotoxins or other agents. In the case of monolayer
cultures of the adenocarcinoma cell lines, tumour cells were
plated in 24-well sterile tissue culture plates at 5 x 104 cells
per well. The plates were incubated for 48 h at 37°C to allow
cell adherence and then treated with test samples for 24 h.
Cultures were incubated for a further 4 h or 24 h in the
presence of 1 gCi of [3H]leucine. Cells were then harvested
and counted for [3H]leucine incorporation.
Results
Effects ofcluster 2 Mabs in the indirect assay ofimmunotoxin
cytotoxicity relative to cell binding
In the indirect assay of immunotoxin cytotoxicity, NCI-H69
cells were exposed to Workshop Mabs, the cells were washed
to remove unbound Mab, and were then incubated in the
presence of the appropriate screening agent at a concentra-
tion, 1 x 10-0M, which did not significantly inhibit
[3H]leucine incorporation in the absence of Mab. The effects
on [3H]leucine incorporation when the cells were treated with
cluster 2 Mabs are shown in Figure la. The results have been
plotted against the relative MFI of cells treated with each
Mab sample as determined by indirect immunofluorescence
and flow cytometry.
The majority of cluster 2 Mabs, including duplicate
samples of MOC-31, mediated potent cytotoxic effects in
combination with the screening agent reducing [3H]leucine
incorporation by greater than 90%. The single exception was
the Mab MOC-151 which reduced [3H]leucine incorporation
by less than 20%. Although all the Mabs bound to greater
than 95% of NCI-H69 cells, MOC-151 bound in lesser
amount suggesting a possible explanation for the weaker
effect with this Mab.
In a subsequent experiment, serial dilutions of hybridoma
supernatants containing the cluster 2 Mabs MOC-31 and
MOC-151 were compared by the indirect immunotoxin assay
and indirect immunofluorescence. At similar levels of binding
to NCI-H69 cells, MOC-31 and MOC-151 mediated a similar
reduction in [3H]leucine incorporation in combination with
the screening agent (Figure lb). This result indicated that
MOC-151 shares with the other cluster 2 Mabs the property
of mediating the efficient entry of ricin A chain provided that
it binds to the cells at a similar level.
Selective cytotoxic effects ofMOC-31 in the indirect assay of
immunotoxin cytotoxicity
Control experiments were performed to verify that the potent
cytotoxic effects of the cluster 2 Mab MOC-31 in the indirect
assay were dependent upon selective binding of the intact
screening agent to the cell-bound Mab. Figure 2a demon-
strates that NCI-H69 cells treated with the purified MOC-31
Mab alone suffered no reduction in [3H]leucine incorporation
compared with untreated cells. In comparison, a large
cytotoxic effect was observed when MOC-31-treated cells
were incubated in the presence of SAMIgG Fab'-ricin A
chain. No significant reduction in [3H]leucine incorporation
was observed when NCI-H69 cells which had been exposed
to MOC-31 were incubated with the alkylated SAMIgG Fab'
fragment, with unconjugated ricin A chain, with a simple
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Figure 1 The relationship between the relative amounts of
cluster 2 Mabs binding to NCI-H69 cells and their ability to
mediate potent cytotoxic effects in the indirect assay of
immunotoxin cytotoxicity. a, NCI-H69 cells exposed to cluster 2
Workshop Mab samples were subjected to the indirect
immunotoxin assay and indirect immunofluorescence (see
'Materials and methods'). The results of the indirect assay are
expressed as the incorporation of [3H]leucine as a percentage of
control cultures lacking screening agent. Points represent mean
values of triplicate determinations. b, NCI-H69 cells exposed to
dilutions of hybridoma supernatants containing MOC-31 (0)
and MOC-151 (-) were analysed by the indirect assay and
indirect immunofluorescence. The incorporation of [3H]leucine is
given as a percentage of untreated control cultures. Each point
represents the mean of triplicate determinations. The error bars
denote the standard deviations from the mean unless too small to
be discerned.
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,creening agent, or assay, cells were exposed to MOC-31, washed to remove
icin A chain. This unbound Mab, and incubated with the screening agent at a
icin A chain to the single concentration of 1 x 10'8 M. In the second arm of the
for MOC-31 to assay, cells were exposed to MOC-31 and then incubated
with the screening agent without the washing step. Com-
s seen with MOC- parison of the results using the two protocols revealed that
t, the combination the washing step made little difference to the cytotoxic effects
he screening agent (Figure 3a). In each case, the IC50 was about 1 x 10-12 M and
differ with statis- [3H]leucine incorporation was inhibited by about 95% when
in the experiment cells were treated with MOC-31 at a concentration of
t, the combination 1 x 10-9 M. However, at the highest concentration of MOC-
found to be non- 31, 1 x 108 M, a reduction in the cytotoxic effect was
M, to which bind- observed when the washing step was omitted.
cted by indirect The indirect assay predicted that a MOC-31 immunotoxin
(not shown). This made by the direct chemical attachment of ricin A chain
wts observed with would be potently cytotoxic to NCI-H69 cells in tissue cul-
the indirect assay ture. In a cytotoxocity experiment analogous with the
target antigen on indirect assay, MOC-31-ricin A chain was incubated with
cells, the cells were washed and then incubated in fresh
medium. In this assay, the IC50 determined was only
3 x 10 '°M, i.e. approximately 300-fold higher than that e indirect assaj, predicted by the indirect assay (Figure 3b). Thus, the indirect
ztotoxic activity of assay had grossly over-estimated the cytotoxic potency of
In one arm of the MOC-31-ricin A chain. In contrast, when the assay was
performed by exposing cells to MOC-31 at different concen-
trations, washing and then incubating in the presence of the
a screening agent at concentrations precisely matched to those
of MOC-31, the IC50 determined was 3 x 10-1 M, exactly
equivalent to that of MOC-31-ricin A chain (Figure 3b).
Two other experiments were performed. Firstly, the effect
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Figure 2 Cytotoxic effects of MOC-31 and W3/25 in combina-
tion with the screening agent and other agents. NCI-H69 cells
exposed to a, MOC-31 and b, W3/25 at a concentration of
1 x 10-8M for 30 min on ice were incubated in the presence of the
agents indicated at a concentration of I x 10-8M for 48 h. The
results are expressed as a percentage of the [3H]leucine incor-
porated by untreated control cultures. Each point represents the
mean of triplicate determinations. The errors bars denote the
standard deviations from the mean values.
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Figure 3 Factors influencing the predictive accuracy of the
indirect assay. a, NCI-H69 cells pretreated with MOC-31 at the
concentrations shown were either washed (0) or not washed (0)
and then incubated with the screening agent at a concentration of
I x 10-8M. b, NCI-H69 cells pretreated with MOC-31-ricin A
chain at the concentrations indicated were washed and incubated
in medium alone (-), or cells pretreated with MOC-31 at the
concentrations indicated were incubated in the presence of the
screening agent at matching concentrations (0). Each point
represents the mean values of triplicate determinations. The
errors bars show the standard deviations from the mean values.
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of a limited exposure to screening agent was tested. MOC-31-
treated cells were incubated with the screening agent on ice
for 30 min, were washed and then incubated in the absence
of screening agent. The effects of this treatment upon
[3H]leucine incorporation were indistinguishable to the effects
of treating cells in the continuous presence of the screening
agent (not shown). Secondly, the effect of binding the
SAMIgG Fab' fragment to the direct A chain immunotoxin
was tested. Cells which had been exposed to MOC-31-ricin A
chain were incubated in the continuous presence of alkylated
SAMIgG Fab' fragment at a concentration of 1 x 10-8 M.
This treatment did not enhance the cytotoxic activity of
MOC-31-ricin A chain (not shown).
Specificity ofMOC-31-ricin A chain action
The toxic effects of a continuous 48 h exposure to MOC-31-
ricin A chain were tested with the NCI-H69 cell line in tissue
culture in parallel with an isotype-matched control immuno-
toxin of irrelevant specificity, W3/25-ricin A chain, with
unconjugated ricin A chain, and the unconjugated MOC-31
Mab. Figure 4a shows a representative concentration-activity
curve.
MOC-31-ricin A chain was toxic to NCI-H69 cells in a
concentration-dependent fashion with an IC50 of about
3 x 10-" M, approximately 1,000-fold lower than the concen-
tration of unconjugated ricin A chain required to reduce
[3H]leucine incorporation by the same amount. At a concen-
tration of 1 x 10-8 M, MOC-31-ricin A chain reduced [3H]-
leucine incorporation by about 95%. In contrast, the isotype-
matched control immunotoxin was only weakly cytotoxic and
unconjugated MOC-31 Mab had no effect at the same con-
centrations. The IC50 of MOC-31-ricin A chain in this con-
tinuous assay was 10-fold lower than in the discontinuous
assay shown in Figure 3b presumably reflecting a greater
uptake of immunotoxin upon prolonged incubation. How-
ever, this ICm was still 30-fold higher than that determined
by the indirect assay (Figure 3a).
Unconjugated MOC-31 at a concentration of 1 x 1O-7M
inhibited the selective cytotoxic action of MOC-31-ricin A
chain whereas the isotype-matched control Mab W3/25 could
not block the action of the immunotoxin (Figure 4b)
indicating that the antigen binding sites of MOC-31 were
responsible for binding the immunotoxin to the cell surface.
Toxic effects ofMOC-31-ricin A chain against a panel of
human tumour cell lines
The cytotoxic activity of MOC-31-ricin A chain was assessed
against a panel of human tumour cell lines in tissue culture in
parallel with W3/25-ricin A chain, unconjugated ricin A
chain and ricin toxin (Table I).
Ricin was potently toxic to all the cell lines in the panel
with IC50 values which ranged between 2.9 x 10-13 M and
4.5 x 10-12 M. MOC-31-ricin A chain was potently toxic to
the SW2, NCI-H69 and GLC-8 SCLC cell lines with ICs
values which ranged between 2.8 x 10-" M and
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Figure 4 Toxic effects of MOC-31-ricin A chain and other
agents against the NCI-H69 cell line in tissue culture. a, NCI-
H69 cells were incubated for 48 h in the continuous presence of
MOC-31-ricin A chain (O), W3/25-ricin A chain (0), MOC-31
(0), or ricin A chain (l) at the concentrations shown, and for a
further 4 h in the presence of [3H]leucine. b, NCI-H69 cells were
incubated for 48 h in the presence of MOC-31-ricin A chain at
the concentrations shown, either alone (U) or in the presence of
MOC-31 (0) or W3/25 (0) each at a concentration of
1 x 10-7M, and then for a further 4h in the presence of
[3H]leucine. The results are expressed as a percentage of the
[3H]leucine incorporated by untreated control cultures. Each
point represents the mean values of quadruplicate a, or triplicate
b, determinations. The error bars denote the standard deviations
from the mean.
2.3 x 10-1 M. In contrast, W3/25-ricin A chain and uncon-
jugated ricin A chain were only weakly toxic to the SCLC
cell lines with ICms of greater than 1 X 10-8 M. MOC-31-ricin
A chain was also potently toxic to the NCI-H125 lung
adenocarcinoma cell line, which expresses the cluster 2
antigen, with an IC50 of 6.5 x 10-"I M.
MOC-31-ricin A chain demonstrated no selective toxic
effects against the NCI-H23 lung adrenocarcinoma cell line
Table I Cytotoxic effects of MOC-31-ricin A chain, W3/25-ricin A chain, ricin A chain and ricin
against human tumour cell lines in tissue culture. a, SCLC cell lines. b, Other cell lines
Agent IC50a(M)
(A) SW2 NCI-H69 GLC-8
MOC-31-ricin A chain 2.3 ± 1.6 x 10-10 2.8 ± 2.1 x 10-11 1.6 ± 1.1 x 10-rn
W3/25-ricin A chain 3.5 ± 0.6 x 10-8 > 1.0 x 10-7 > 1.0 X 10-7
Ricin A chain 3.2 ± 0.2 x 10-8 2.6 ± 0.4 x 10-8 5.8 ± 2.3 x 10-8
Ricin 2.9 ± 1.7 x 10-13 7.9 ± 3.2 x 10-13 4.5 ± 0.1 x 10- 12
(B) NCI-H23 NCI-H125 CEM
MOC-31-ricin A chain > 1.0 x 10-8 6.5 ± 5.3 x 10-" > 1.0 x 10-7
W3/25-ricin A chain > 1.0 x 10-8 > 1.0 x 10-8 > 1.0 x 10-8
Ricin A chain > 1.0 x 10-8 > 1.0x 10-8 > 1.0 x 10-8
Ricin 5.1 ± 0.9 x 10-13 6.3 ± 1.8 x 10-13 1.4 ±0.2 x 10-12
aThe IC50s given are the mean values and standard deviations of at least three independent
experiments and are quoted in terms of A chain concentration.
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to which binding of MOC-31 could not be detected by
indirect immunofluorescence and flow cytometry. The
antigen-negative CEM cell line was also unaffected by the
MOC-3 1 immunotoxin indicating that the action of the
immunotoxin was selective for cells expressing the target
antigen.
Discussion
In this study, we have examined the specificity and accuracy
of an indirect assay of immunotoxin cytotoxicity and the
cytotoxic effects of an immunotoxin prepared with the Mab
MOC-31 which recognises the cluster 2 antigen associated
with human SCLC. The main findings of the study were: (i)
similar selective cytotoxic effects were observed in the indirect
assay with cluster 2 Mabs when bound to the NCI H69
SCLC cell line in similar amounts, (ii) the indirect assay
grossly over-estimated the cytotoxic potency of MOC-31-
ricin A chain except when the concentration of the screening
agent was precisely matched to that of the Mab, and (iii)
MOC-31-ricin A chain was potently and selectively toxic to
human lung carcinoma cell lines expressing the cluster 2
antigen in tissue culture.
In a screen of Mabs from the Second International Work-
shop on SCLC Antigens by the indirect assay of immuno-
toxin cytotoxicity, the Mabs that mediated the most
profound cytotoxic effects against the NCI-H69 cell line were
those belonging to cluster 2 (Derbyshire & Wawrzynczak,
1991). This finding actually assisted in identifying some of
the Mabs finally assigned to cluster 2 (Souhami et al., 1991).
In the initial screen, MOC-151 was the only cluster 2 Mab
that bound to greater than 95% of NCI-H69 cells yet failed
to mediate potent cytotoxic effects. In the present study,
MOC-151 was shown to mediate cytotoxic effects similar to
those of the effective cluster 2 Mab MOC-31 when the two
Mabs bound to NCI-H69 cells in similar amounts, suggesting
that MOC-151 had been ineffective in the initial screen
because insufficient Mab had bound to the cell surface. Since
both MOC-31 and MOC-151 were present in the Workshop
panel at a concentration of about 1 x l0-7 M (Manderino,
1991), the lower binding of MOC-151 might have reflected a
lower avidity of binding or simply deterioration of the sam-
ple with time.
The method by which the indirect assay was performed
was dictated by the nature of the Workshop Mab samples.
Firstly, it had been necessary to include a washing step to
remove sodium azide and any unknown contaminants pres-
ent in the samples that might have affected cell viability. In
this respect, the method used in this study necessarily
deviated from the protocol recommended by Till et al. (1988)
who screened purified Mabs without including a washing
step. In the present study, the washing step was found to
have little effect upon the cytotoxicity of MOC-31 in com-
bination with the screening agent except at the highest con-
centration of Mab tested. This effect, similar to that de-
scribed by Till et al. (1988), may have been caused by excess
unbound Mab reacting with the screening agent and preven-
ting it from binding to the cell-bound Mab. Our results
suggest that a washing step may actually be beneficial when
screening Mab solutions of unknown concentrations.
Secondly, it had been necessary to use a fixed concentration
of the screening agent in the indirect assay because the
precise concentrations of Mab within the samples were un-
known. Performing the assay in this way led to a 300-fold
over-estimation in the potency of the MOC-31-ricin A chain
immunotoxin.
A number of explanations for the apparent discrepancy
between the actual potency of the MOC-31 immunotoxin and
the potency estimated by the indirect assay were considered.
Firstly, repeated rounds of MOC-3 1 internalisation might
have allowed the prolonged uptake of the screening agent
when present in excess. However, this explanation appeared
unlikely because washing away unbound screening agent did
not diminish the cytotoxic effect observed. Secondly, simple
binding of the screening agent to MOC-31 might have in-
creased internalisation of the Mab to intracellular compart-
ments favouring ricin A chain translocation to the cytosol.
However, the cytotoxic activity of MOC-31-ricin A chain was
not enhanced in the presence of Fab' fragment suggesting
that binding of the Fab' per se was unlikely to have altered
the route of Mab entry into the cells.
Finally, we considered the possibility that the binding of
multiple screening agent molecules to each molecule of
MOC-31 led to a higher cytotoxic efficacy in the indirect
assay. In support of this explanation, we found that the
indirect assay did accurately measure the cytotoxic potency
of MOC-31-ricin A chain when the concentration of the
screening agent was precisely matched to that of MOC-31
thus mirroring the proportions of A chain and Mab in the
MOC-31-ricin A chain immunotoxin. In the presence of
excess screening agent, delivery of multiple Fab'-A chain
molecules by each molecule of Mab could result in a higher
delivery of ricin A chain into cells. Alternatively, even though
multiple Fab' fragments binding to MOC-31-ricin A chain
did not enhance immunotoxin cytotoxicity, the multiple
molecules of ricin A chain internalised with MOC-31 in the
indirect assay may have altered the intracellular fate of the
Mab and enhanced the process of intoxication.
In the case of the cluster 2 Mab MOC-31, theICo deter-
mined by the indirect immunotoxin assay was strongly
influenced by the concentration of screening agent used. The
accuracy of the indirect assay also appears to depend on the
target antigen recognised by the Mab because, in a previous
study, we identified that the indirect assay did in fact
accurately predict the cytotoxic potency of a ricin A chain
immunotoxin recognising a different SCLC-associated
antigen (Wawrzynczak et al., 1990). Till et al. (1988) also
reported a variability in the predictive accuracy of their
indirect assay. In most cases, the cytotoxic effects of the
indirect assay were closely similar to those of the ricin A
chain immunotoxins but the activity of one immunotoxin
was under-estimated by more than 30-fold. It would
therefore seem imprudent to rely on the indirect assay to
accurately predict the absolute potency of ricin A chain
immunotoxins recognising different antigens.
Although MOC-31-ricin A chain was not as potently toxic
as predicted by the indirect assay, the immunotoxin was
shown to be selectively toxic to all three SCLC cell lines
examined upon continuous exposure for 48 h. In addition to
the three SCLC cell lines, MOC-31-ricin A chain was toxic to
the NCI-H125 lung adrenocarcinoma cell line which ex-
presses the target antigen. The cluster 2 antigen is an
epithelial cell-surface glycoprotein with a molecular mass of
about 35 kDa (Perez & Walker, 1989; Strnad et al., 1989;
Durbin et al., 1990). This antigen has a similar predicted
amino acid sequence to other cloned antigens (Linnenbach et
al., 1989; Simon et al., 1990). These data unite the cluster 2
Mabs identified in the Workshop with other Mabs that
appear to recognise the same or closely related antigens.
Two cluster 2-related Mabs, namely 17-lA and LDI, have
previously been chemically linked to ricin A chain (Gilliland
et al., 1980; Blakey et al., 1993). The immunotoxins were
found to be selectively toxic to human colorectal carcinoma
cells in tissue culture, with ICms of 1-3 x 10-10 M, but their
activities against lung carcinomas have not been reported.
Immunoconjugates of cluster 2-related Mabs and
chemotherapeutic drugs have been administered systemically
to patients with a variety of adenocarcinomas. However,
other studies have indicated that the target antigen is present
and accessible to intravenously administered Mab on normal
gastric mucosa in vivo (Shen et al., 1984; Elias et al., 1990).
Whether this normal tissue reactivity would prove a serious
limitation of immunotoxin therapy remains to be determined.
In conclusion, the cytotoxic effects measured by the
indirect immunotoxin assay are sensitive to the nature of the
target antigen, to the amount of Mab that binds to the target
cell surface and to the relative molar amounts of Mab and
screening agent. The results of indirect screens with Mabs
which recognise different antigens cannot be relied upon toSMALL CELL LUNG CANCER IMMUNOTOXIN 1247
give a accurate guide to the relative potency of the corres-
ponding directly-linked A chain ITs unless the Mab concent-
rations are defined and the concentration of the screening
agent is precisely matched to that of the Mab.
This work was supported by the Cancer Research Campaign,
London UK.
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